search icon
  • Print
  • ShareThis
  • Text Size
  • Emerging Infections & Biothreats

    Public health emergencies caused by infectious threats have the potential to kill thousands or millions of people. These threats can emerge naturally as outbreaks or pandemics, such as influenza (pandemic and seasonal), severe acute respiratory syndrome (SARS), extremely-drug resistant (XDR) tuberculosis, New Delhi metallo-b-lactamase 1 (NDM1), antibiotic-resistant bacterial infections, and HIV/AIDS. Or, they can emerge deliberately through bioterrorism, such as the 2001 anthrax attacks or potential threats posed by smallpox, tularemia, and plague. Infectious threats can undermine not only patient care and public health, but also national security. Influenza pandemics, for example, have a long history of devastation in terms of lives lost, hospitalizations, and destabilizing national economies. 
     

    Each day, infectious diseases physicians and scientists serve on the front lines in protecting us from such threats. IDSA advances U.S. preparedness and response initiatives by promoting appropriate action by health care providers, strengthened public health and research efforts, development of life-saving countermeasures (vaccines, drugs and diagnostics), and implementation of appropriate non-therapeutic control measures.

    IDSA’s Efforts on Public Health Emergencies and Biothreats

    4/2/2012

    IDSA Comments on Doxycycline Medkits (PDF)

    At a joint meeting of FDA advisory committees regarding development of a doxycycline home MedKit, IDSA provided public comments on prepositioning in the event of an anthrax release.
    9/29/2010

    IDSA Testimony on Medical Countermeasures Enterprise Review (PDF)

    Dr. Andy Pavia testified on behalf of IDSA at a September 29, 2010 hearing of the Senate Labor-Health and Human Services-Education Appropriations Subcommittee examining the Public Health Emergency Medical Countermeasures Enterprise review completed by the Department of Health and Human Services in August 2010.
    10/29/2008

    IDSA Comments on the Development of Influenza Antiviral Home MedKits (PDF)

    At a meeting of FDA advisory committee regarding development of an influenza antiviral home MedKit, IDSA provided public comments about the challenges to safe and effective use posed by the unknowns regarding use of current antivirals in a pandemic, combined with the absence of medical supervision in the proposed scenario of home based use.
    6/18/2008

    IDSA Preliminary Statement on Antibiotic Home Stockpiling (PDF)

    At a meeting of the National Biodefense Science Board, IDSA delivered public comments raising concerns about an HHS initiative to inform the public about home stockpiling of doxycycline for use in a potential anthrax attack.
    12/21/2011

    IDSA Comments on FDA Development of Multiplexed Diagnostics (PDF)

    FDA sought comments on options being considered for the performance validation of highly multiplexed microbiology/medical countermeasure (MCM) diagnostic devices.  In responding to the FDA concept paper, IDSA addressed the clinical and public health need for better infectious diseases diagnostic devices, clinical considerations for device design, and key issues for device validation.
    12/2/2011

    IDSA Comments on Select Agents and Toxins Proposed Rule (PDF)

    IDSA conveyed its appreciation to CDC/HHS for aspects of the Proposed Rule that provide greater clarification for managing select agents and toxins.  However, IDSA offered five overarching recommendations that improve biosecurity while taking into account the impact of regulations on research essential to public health and national security.
    6/26/2009

    IDSA Outlines Priorities for FDA's Incoming Leaders (PDF)

    In a letter to Commissioner Peggy Hamburg, IDSA requested a meeting with top agency officials to discuss issues and strategies related to novel H1N1 influenza, impediments to antibacterial drug development, strategies to better address antimicrobial resistance and the use of antimicrobials in animals.
    10/29/2008

    IDSA Comments on the Development of Influenza Antiviral Home MedKits (PDF)

    At a meeting of FDA advisory committee regarding development of an influenza antiviral home MedKit, IDSA provided public comments about the challenges to safe and effective use posed by the unknowns regarding use of current antivirals in a pandemic, combined with the absence of medical supervision in the proposed scenario of home based use.
    2/15/2012

    IDSA Comments on Preparedness Legislation (PDF)

    IDSA sent a letter to congressional sponsors of House and Senate legislation to reauthorize the Pandemic and All Hazards Preparedness Act (PAHPA) urging that key provisions from each chambers' proposal be included in the final legislation.
    11/22/2011

    IDSA Letter to Senate Sponsors of the Pandemic and All Hazards Preparedness (PAHPA) Reauthorization Act (PDF)

    IDSA commends the PAHPA Reauthorization Act and encourages new provisions to incentivize antibiotic R&D, provide federal leadership to explore options for public private partnerships to focus on early antibiotic discovery research, and strengthen influenza preparedness and response.
    8/19/2011

    IDSA Letter to Senate Committee Regarding Reauthorization of the Pandemic All Hazards Preparedness Act (PAHPA) (PDF)

    IDSA urges Congress to address antibiotic and related diagnostics development and antibiotic resistance coordination issues including through creation of an HHS-supported Strategic Investment Firm and an NIH-supported ID clinical specimen repository.
    11/30/2010

    IDSA Urges Appropriators to Fund Medical Countermeasures Review Recommendations (PDF)

    IDSA sent a letter to all members of the House and Senate Appropriations Committees urging funding to implement fully the recommendations continued in the Administration's Medical Countermeasures Review report which was issued in August.
    9/7/2011

    Biodefense since 9/11: The Price of Protection

    Hayden, Nature vol. 477 no. 7363 September 7 2011 150-152.
    11/30/2011

    Information Sharing and Collaboration: Applications to Integrated Biosurveillance--Workshop Summary

    Public Workshop Summary, Institute of Medicine Workshop on Information Sharing and Collaboration:  Applications to Integrated Biosurveillance November 30, 2011.

     

    Summary of an Institute of Medicine workshop exploring the information-sharing and collaboration processes needed for the nation's integrated biosurveillance strategy.

    10/4/2011

    Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan 2011-2016

    The BARDA Strategic Plan defines a set of core principles that will improve BARDA's ability to manage resources efficiently, strengthen public-private partnerships, and promote the broad categories of countermeasures that BARDA is most interested in pursuing to protect health and save lives in a public health emergency.
    3/13/2012

    The Project Bioshield Act: Issues for the 112th Congress (PDF)

    Grotton, Congressional Research Service March 13, 2012.

    A report on the Project Bioshield Act that gives the federal government new authorities over the development, procurement, and use of medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) terrorism agents.  Congress is currently considering whether these authorities have sufficiently contributed to national preparedness to merit extension.

 

Average 0 out of 5

| HIVMA | Contact Us

© Copyright IDSA 2012 Infectious Diseases Society of America

Full Site Mobile Site